10X Genomics, Inc. Financials
10X Genomics, Inc. (TXG) reported $642.8M in revenue for fiscal year 2025, up 5.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Cash conversion inflected sharply as operating losses shrank and working-capital demands eased, making FY2025 a self-funded year.
Between FY2024 and FY2025, operating cash flow swung from$6.7M to$136.1M , a much bigger improvement than the top line alone would imply. With receivables and inventory both lower while revenue still grew, and capex down to$5.9M , the company stopped tying cash up inside growth and turned most operating cash into free cash flow.
The profit recovery came mainly below gross profit: gross margin in FY2025 was only
The balance sheet remains equity-funded rather than creditor-funded, with cash of
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of 10X Genomics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
10X Genomics, Inc. scores 19.36, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($8.3B) relative to total liabilities ($245.0M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
10X Genomics, Inc. passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
10X Genomics, Inc. reported a net loss of $43.5M while generating $136.1M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
10X Genomics, Inc. generated $642.8M in revenue in fiscal year 2025. This represents an increase of 5.2% from the prior year.
10X Genomics, Inc.'s EBITDA was -$24.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 84.4% from the prior year.
10X Genomics, Inc. reported -$43.5M in net income in fiscal year 2025. This represents an increase of 76.2% from the prior year.
10X Genomics, Inc. earned -$0.35 per diluted share (EPS) in fiscal year 2025. This represents an increase of 77.0% from the prior year.
Cash & Balance Sheet
10X Genomics, Inc. generated $130.1M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 2371.2% from the prior year.
10X Genomics, Inc. held $474.0M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
10X Genomics, Inc.'s gross margin was 69.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 1.2 percentage points from the prior year.
10X Genomics, Inc.'s operating margin was -9.5% in fiscal year 2025, reflecting core business profitability. This is up 22.4 percentage points from the prior year.
10X Genomics, Inc.'s net profit margin was -6.8% in fiscal year 2025, showing the share of revenue converted to profit. This is up 23.1 percentage points from the prior year.
10X Genomics, Inc.'s ROE was -5.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 20.3 percentage points from the prior year.
Capital Allocation
10X Genomics, Inc. invested $238.6M in research and development in fiscal year 2025. This represents a decrease of 9.8% from the prior year.
10X Genomics, Inc. invested $5.9M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 52.1% from the prior year.
Not reported for fiscal year 2025.
TXG Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $616.9M | $642.8M+5.2% | $610.8M-1.3% | $618.7M+19.8% | $516.4M+5.3% | $490.5M+64.1% | $298.8M+21.5% | $245.9M+68.1% | $146.3M+105.8% | $71.1M |
| Cost of Revenue | $184.9M | $198.9M+1.3% | $196.3M-6.3% | $209.4M+74.0% | $120.4M+62.5% | $74.1M+26.7% | $58.5M-4.2% | $61.0M+112.9% | $28.7M+171.4% | $10.6M |
| Gross Profit | $432.0M | $443.9M+7.1% | $414.5M+1.3% | $409.3M+3.4% | $396.0M-4.9% | $416.4M+73.2% | $240.4M+30.0% | $184.9M+57.1% | $117.7M+94.4% | $60.5M |
| R&D Expenses | $226.8M | $238.6M-9.8% | $264.7M-2.1% | $270.3M+1.8% | $265.7M+25.5% | $211.8M+71.6% | $123.4M+48.5% | $83.1M+74.8% | $47.5M+47.8% | $32.2M |
| SG&A Expenses | $297.0M | $316.1M-8.2% | $344.3M+0.3% | $343.3M+15.1% | $298.3M+15.8% | $257.6M+27.3% | $202.3M+54.6% | $130.8M+48.8% | $87.9M+88.2% | $46.7M |
| Operating Income | -$88.4M | -$61.0M+68.7% | -$194.6M+26.7% | -$265.3M-58.0% | -$167.9M-221.4% | -$52.3M+90.2% | -$534.1M-1647.1% | -$30.6M+72.4% | -$110.8M-502.8% | -$18.4M |
| Interest Expense | N/A | $0-100.0% | $4K-87.9% | $33K-93.1% | $476K-45.0% | $866K-48.5% | $1.7M-45.4% | $3.1M+27.8% | $2.4M+197.0% | $811K |
| Income Tax | $235K | $3.6M-26.2% | $4.9M-22.2% | $6.3M+57.3% | $4.0M-10.6% | $4.5M-45.4% | $8.3M+3686.7% | $218K+150.6% | $87K+314.3% | $21K |
| Net Income | -$75.1M | -$43.5M+76.2% | -$182.6M+28.4% | -$255.1M-53.7% | -$166.0M-185.2% | -$58.2M+89.3% | -$542.7M-1636.7% | -$31.3M+72.2% | -$112.5M-499.5% | -$18.8M |
| EPS (Diluted) | — | -$0.35+77.0% | -$1.52+30.3% | -$2.18-49.3% | -$1.46-175.5% | -$0.53+90.1% | -$5.37 | -$0.80 | N/A | N/A |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
TXG Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.0B+13.4% | $918.6M-4.8% | $965.1M-6.2% | $1.0B+1.0% | $1.0B+9.6% | $929.3M+53.4% | $605.9M+387.4% | $124.3M | N/A |
| Current Assets | $684.5M+17.1% | $584.4M-2.0% | $596.0M-6.1% | $635.0M-15.1% | $747.6M-3.5% | $774.4M+61.0% | $480.8M+352.6% | $106.2M | N/A |
| Cash & Equivalents | $474.0M+37.8% | $344.1M-4.2% | $359.3M+63.5% | $219.7M-62.6% | $587.4M-11.5% | $663.6M+56.4% | $424.2M+551.8% | $65.1M+36.0% | $47.9M |
| Inventory | $56.3M-32.2% | $83.1M+12.8% | $73.7M-9.7% | $81.6M+36.1% | $60.0M+100.2% | $30.0M+96.2% | $15.3M+78.2% | $8.6M | N/A |
| Accounts Receivable | $47.0M-46.5% | $87.9M-23.5% | $114.8M+10.2% | $104.2M+22.2% | $85.3M+66.5% | $51.2M+53.5% | $33.4M+18.8% | $28.1M | N/A |
| Goodwill | $4.5M0.0% | $4.5M0.0% | $4.5M0.0% | $4.5M0.0% | $4.5M | $0 | N/A | N/A | N/A |
| Total Liabilities | $245.0M+17.5% | $208.5M-7.0% | $224.1M+0.4% | $223.2M+10.9% | $201.3M+5.8% | $190.3M+2.4% | $185.8M-46.0% | $344.3M | N/A |
| Current Liabilities | $153.5M+30.5% | $117.6M-7.5% | $127.2M-2.9% | $131.0M+18.7% | $110.4M-6.6% | $118.1M+87.4% | $63.0M+94.8% | $32.4M | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | $0-100.0% | $19.8M-22.2% | $25.5M | N/A |
| Total Equity | $796.3M+12.1% | $710.1M-4.2% | $741.0M-8.0% | $805.7M-1.4% | $817.6M+10.6% | $739.1M+75.9% | $420.1M+291.0% | -$220.0M-95.5% | -$112.5M |
| Retained Earnings | -$1.5B-3.0% | -$1.5B-14.2% | -$1.3B-24.8% | -$1.0B-19.2% | -$863.3M-7.2% | -$805.1M-206.9% | -$262.4M-13.5% | -$231.1M | N/A |
TXG Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $127.1M | $136.1M+1941.6% | $6.7M+143.9% | -$15.2M+54.8% | -$33.6M-57.2% | -$21.4M+90.2% | -$217.9M-729.3% | $34.6M+145.3% | -$76.4M-614.2% | -$10.7M |
| Capital Expenditures | $5.6M | $5.9M-52.1% | $12.4M-74.5% | $48.6M-63.1% | $131.7M+30.0% | $101.3M+176.2% | $36.7M-14.2% | $42.7M+580.2% | $6.3M+67.3% | $3.8M |
| Free Cash Flow | $121.4M | $130.1M+2371.2% | -$5.7M+91.0% | -$63.8M+61.4% | -$165.3M-34.7% | -$122.7M+51.8% | -$254.6M-3037.0% | -$8.1M+90.2% | -$82.7M-472.1% | -$14.5M |
| Investing Cash Flow | -$19.7M | -$13.4M+58.8% | -$32.6M-124.4% | $133.5M+138.0% | -$350.9M-228.8% | -$106.7M-178.0% | -$38.4M+10.2% | -$42.8M-537.5% | -$6.7M-78.6% | -$3.8M |
| Financing Cash Flow | -$2.5M | $6.8M-37.7% | $10.9M-20.2% | $13.7M-13.6% | $15.8M-55.2% | $35.3M-92.5% | $468.9M+13.1% | $414.6M+293.5% | $105.4M+411.9% | $20.6M |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $80K |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
TXG Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 69.0%+1.2pp | 67.9%+1.7pp | 66.1%-10.5pp | 76.7%-8.2pp | 84.9%+4.4pp | 80.4%+5.3pp | 75.2%-5.2pp | 80.4%-4.7pp | 85.1% |
| Operating Margin | -9.5%+22.4pp | -31.9%+11.0pp | -42.9%-10.4pp | -32.5%-21.9pp | -10.7% | -178.7% | -12.4%+63.3pp | -75.7%-49.9pp | -25.9% |
| Net Margin | -6.8%+23.1pp | -29.9%+11.3pp | -41.2%-9.1pp | -32.1%-20.3pp | -11.9% | -181.6% | -12.7%+64.2pp | -76.9%-50.5pp | -26.4% |
| Return on Equity | -5.5%+20.3pp | -25.7%+8.7pp | -34.4%-13.8pp | -20.6%-13.5pp | -7.1%+66.3pp | -73.4%-66.0pp | -7.4% | N/A | N/A |
| Return on Assets | -4.2%+15.7pp | -19.9%+6.5pp | -26.4%-10.3pp | -16.1%-10.4pp | -5.7%+52.7pp | -58.4%-53.2pp | -5.2%+85.3pp | -90.5% | N/A |
| Current Ratio | 4.46-0.5x | 4.97+0.3x | 4.69-0.2x | 4.85-1.9x | 6.77+0.2x | 6.56-1.1x | 7.63+4.3x | 3.28 | N/A |
| Debt-to-Equity | 0.310.0x | 0.290.0x | 0.300.0x | 0.280.0x | 0.25+0.2x | 0.000.0x | 0.05 | N/A | N/A |
| FCF Margin | 20.2%+21.2pp | -0.9%+9.4pp | -10.3%+21.7pp | -32.0%-7.0pp | -25.0%+60.2pp | -85.2%-81.9pp | -3.3%+53.2pp | -56.5%-36.2pp | -20.3% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Where 10X Genomics, Inc. Ranks
Frequently Asked Questions
What is 10X Genomics, Inc.'s annual revenue?
10X Genomics, Inc. (TXG) reported $642.8M in total revenue for fiscal year 2025. This represents a 5.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is 10X Genomics, Inc.'s revenue growing?
10X Genomics, Inc. (TXG) revenue grew by 5.2% year-over-year, from $610.8M to $642.8M in fiscal year 2025.
Is 10X Genomics, Inc. profitable?
No, 10X Genomics, Inc. (TXG) reported a net income of -$43.5M in fiscal year 2025, with a net profit margin of -6.8%.
What is 10X Genomics, Inc.'s EBITDA?
10X Genomics, Inc. (TXG) had EBITDA of -$24.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is 10X Genomics, Inc.'s gross margin?
10X Genomics, Inc. (TXG) had a gross margin of 69.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is 10X Genomics, Inc.'s operating margin?
10X Genomics, Inc. (TXG) had an operating margin of -9.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is 10X Genomics, Inc.'s net profit margin?
10X Genomics, Inc. (TXG) had a net profit margin of -6.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is 10X Genomics, Inc.'s return on equity (ROE)?
10X Genomics, Inc. (TXG) has a return on equity of -5.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is 10X Genomics, Inc.'s free cash flow?
10X Genomics, Inc. (TXG) generated $130.1M in free cash flow during fiscal year 2025. This represents a 2371.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is 10X Genomics, Inc.'s operating cash flow?
10X Genomics, Inc. (TXG) generated $136.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are 10X Genomics, Inc.'s total assets?
10X Genomics, Inc. (TXG) had $1.0B in total assets as of fiscal year 2025, including both current and long-term assets.
What are 10X Genomics, Inc.'s capital expenditures?
10X Genomics, Inc. (TXG) invested $5.9M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does 10X Genomics, Inc. spend on research and development?
10X Genomics, Inc. (TXG) invested $238.6M in research and development during fiscal year 2025.
What is 10X Genomics, Inc.'s current ratio?
10X Genomics, Inc. (TXG) had a current ratio of 4.46 as of fiscal year 2025, which is generally considered healthy.
What is 10X Genomics, Inc.'s debt-to-equity ratio?
10X Genomics, Inc. (TXG) had a debt-to-equity ratio of 0.31 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is 10X Genomics, Inc.'s return on assets (ROA)?
10X Genomics, Inc. (TXG) had a return on assets of -4.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is 10X Genomics, Inc.'s Altman Z-Score?
10X Genomics, Inc. (TXG) has an Altman Z-Score of 19.36, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is 10X Genomics, Inc.'s Piotroski F-Score?
10X Genomics, Inc. (TXG) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are 10X Genomics, Inc.'s earnings high quality?
10X Genomics, Inc. (TXG) reported a net loss of $43.5M while generating $136.1M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is 10X Genomics, Inc.?
10X Genomics, Inc. (TXG) scores 75 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.